KETO-CTA Study Retracted from JACC Over Methodology Flaws, Raising LDL Safety Concerns

A paper that became one of the most-cited defenses of elevated LDL in lean keto dieters has been pulled from JACC: Advances after the journal and the authors agreed the methodology errors were "too great to be corrected with a corrigendum." The retracted study, titled "Plaque Begets Plaque, ApoB Does Not: Longitudinal Data from the KETO-CTA Trial," had been published in April 2025 and quickly circulated in low-carb communities as evidence that sky-high LDL posed no real cardiovascular threat for metabolically healthy individuals on a ketogenic diet.

The paper examined so-called Lean Mass Hyper-Responders (LMHRs), the subset of keto followers who develop dramatically elevated LDL-C on a carbohydrate-restricted diet despite being lean, with high HDL and low triglycerides. The study's authors, led by Adrian Soto-Mota and including Nicholas Norwitz, David Feldman, and Matthew Budoff, reported that neither total exposure nor changes in baseline ApoB and LDL-C were associated with changes in noncalcified plaque volume or total plaque score. Participants carried a median LDL-C of 237 mg/dL and median ApoB of 178 mg/dL, numbers well above standard clinical thresholds.

The central methodological problem was that the study preregistered change in noncalcified plaque volume as its primary outcome, yet that measure received only brief treatment in Figure 1 without proper description. Instead, the authors led with percent atheroma volume, a secondary endpoint, raising concerns of selective reporting. What the headline metric obscured was significant: the pooled median change in noncalcified plaque volume was 18.9 mm3, corresponding to a 42.8% relative change over the study period. The authors later acknowledged in a published reply that omitting this figure from their results narrative "was a sincere oversight, not intentional selective reporting," but by that point JACC had already issued an Expression of Concern. That expression was posted online January 23, 2026, and the retraction followed, with the journal confirming the identified errors rendered the data unreliable.

For keto followers watching this debate, the retraction does not mean that elevated LDL definitively causes plaque progression in metabolically healthy individuals. What it does mean is that the strongest longitudinal evidence used to argue the opposite is now off the table. The original cross-sectional KETO trial, which matched 80 LMHR individuals against controls from the Miami Heart cohort, had already found no difference in plaque burden despite a 149 mg/dL LDL gap between groups. That earlier dataset remains intact, but cross-sectional comparisons can only take you so far in a conversation about progression.

The practical takeaway for anyone running a keto protocol with LDL north of 190 mg/dL is to stop treating this retraction as either a crisis or a non-event, and start treating it as a prompt for smarter monitoring. Get ApoB measured at your next panel; it is more predictive of particle burden than LDL-C alone and was the metric at the center of this entire dispute. Have a conversation with your doctor about a coronary artery calcium (CAC) scan if you have been keto for more than two years with consistently elevated LDL, since the study's own data showed that baseline CAC, not ApoB, was the significant predictor of future plaque changes, making it the most actionable number for individual risk stratification. And take a hard look at fat quality: olive oil, fatty fish, and avocado carry a meaningfully different risk profile than a diet anchored in processed meats and full-fat dairy, even when the macros look identical on paper.

The LMHR hypothesis deserves rigorous testing. This retraction makes that testing more necessary, not less.